Compare Lupin with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ALEMBIC PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN ALEMBIC PHARMA LUPIN/
ALEMBIC PHARMA
 
P/E (TTM) x 46.3 16.4 282.8% View Chart
P/BV x 4.3 6.5 65.4% View Chart
Dividend Yield % 0.5 0.6 86.9%  

Financials

 LUPIN   ALEMBIC PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-20
ALEMBIC PHARMA
Mar-19
LUPIN/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs882664 132.9%   
Low Rs505412 122.5%   
Sales per share (Unadj.) Rs339.4208.7 162.6%  
Earnings per share (Unadj.) Rs-5.931.0 -19.2%  
Cash flow per share (Unadj.) Rs15.537.1 41.7%  
Dividends per share (Unadj.) Rs6.005.50 109.1%  
Dividend yield (eoy) %0.91.0 84.6%  
Book value per share (Unadj.) Rs276.7144.2 191.9%  
Shares outstanding (eoy) m453.00188.52 240.3%   
Bonus / Rights / Conversions ESOP--  
Price / Sales ratio x2.02.6 79.3%   
Avg P/E ratio x-116.617.4 -671.8%  
P/CF ratio (eoy) x44.814.5 309.1%  
Price / Book Value ratio x2.53.7 67.2%  
Dividend payout %-100.917.7 -568.6%   
Avg Mkt Cap Rs m314,201101,461 309.7%   
No. of employees `00018.3NA-   
Total wages/salary Rs m29,8687,467 400.0%   
Avg. sales/employee Rs Th8,400.6NM-  
Avg. wages/employee Rs Th1,632.0NM-  
Avg. net profit/employee Rs Th-147.2NM-  
INCOME DATA
Net Sales Rs m153,74839,347 390.7%  
Other income Rs m4,83894 5,157.4%   
Total revenues Rs m158,58539,441 402.1%   
Gross profit Rs m24,8498,736 284.5%  
Depreciation Rs m9,7021,152 842.0%   
Interest Rs m3,630184 1,971.6%   
Profit before tax Rs m16,3557,493 218.3%   
Minority Interest Rs m411 36.1%   
Prior Period Items Rs m39-93 -42.5%   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5711,568 738.2%   
Profit after tax Rs m-2,6945,844 -46.1%  
Gross profit margin %16.222.2 72.8%  
Effective tax rate %70.820.9 338.2%   
Net profit margin %-1.814.9 -11.8%  
BALANCE SHEET DATA
Current assets Rs m154,13219,577 787.3%   
Current liabilities Rs m92,25214,896 619.3%   
Net working cap to sales %40.211.9 338.3%  
Current ratio x1.71.3 127.1%  
Inventory Days Days8290 91.5%  
Debtors Days Days12945 285.1%  
Net fixed assets Rs m89,08227,097 328.8%   
Share capital Rs m906377 240.3%   
"Free" reserves Rs m124,46126,811 464.2%   
Net worth Rs m125,36727,188 461.1%   
Long term debt Rs m17,9334,993 359.2%   
Total assets Rs m249,83947,778 522.9%  
Interest coverage x5.541.7 13.2%   
Debt to equity ratio x0.10.2 77.9%  
Sales to assets ratio x0.60.8 74.7%   
Return on assets %0.412.6 3.0%  
Return on equity %-2.121.5 -10.0%  
Return on capital %8.723.6 37.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45019,453 264.5%   
Fx outflow Rs m19,4706,065 321.0%   
Net fx Rs m31,98013,388 238.9%   
CASH FLOW
From Operations Rs m14,6888,120 180.9%  
From Investments Rs m11,070-7,556 -146.5%  
From Financial Activity Rs m-8,906590 -1,508.4%  
Net Cashflow Rs m16,8531,153 1,461.2%  

Share Holding

Indian Promoters % 46.6 74.1 62.9%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 2.9 389.7%  
FIIs % 31.9 9.1 350.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 13.9 72.7%  
Shareholders   98,259 49,328 199.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   NOVARTIS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare LUPIN With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 14, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS